No ASX ETF holds Starpharma (SPL) as of 15 Oct 2026. Over the last 3 months it rose 2.7%: on $10,000, +$274. We explain 6 big moves in that time.
About SPL
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$398.2m
- Held by0 ETFs
- Big moves6 in 3M
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −8.6%peak −10.3%1 Oct 2026· Management
A board chair and deputy chair appointment announcement appears to have unsettled investors, driving an outsized sell-off beyond what sector weakness alone can explain.
- +4.3%peak +5.8%13 Aug 2026· Stake Change
Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
- −5.4%12 Aug 2026· Capital Raise
Starpharma launched a $32 million capital raise, causing dilution and a sharp drop in the stock price.
- −7.5%peak −19.9%11 Aug 2026· Capital Raise
Starpharma's stock fell sharply after completing a $32 million renounceable entitlement offer, with new shares being quoted, causing dilution-driven selling pressure.
- +6.7%peak +8.0%5 Aug 2026· Unknown
SPL.AX rose sharply alongside a broader lift in the ASX healthcare sector, likely driven by a general sector rotation or positive sentiment across health stocks rather than any company-specific news.
- +8.0%28 Jul 2026· Sector Flow
SPL.AX rose strongly alongside a broad rally in Australian healthcare sector stocks, lifting the stock on sector-wide buying momentum.
Held by 0 ETFs
No ETF we track holds SPL directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did SPL rise 4.3% on 13 Aug 2026?
Starpharma
Multiple directors purchased shares through the recently completed $32 million entitlement offer, signalling strong insider confidence and prompting a positive market re-rating of the stock.
The most coherent narrative combines two related events: the successful completion of a $32 million entitlement offer on 11 August and the disclosure on 13 August (the day of detection) that at least four directors — Cheryl Maley, Dr Russell Basser, Lynda Cheng, and Robert Thomas — each took up shares in that offer. Insider participation at scale is a well-established positive signal for the market, and the timing of those disclosures aligns closely with the abnormal volume (6.5x) and price move detected. The broader healthcare sector was also mildly positive (~5.4% sector signal), providing a small tailwind but insufficient to explain a 5% single-stock move on its own. No formal ASX company announcement was captured in Layer 1, reducing confidence slightly, but the convergence of director buying disclosures and elevated volume strongly supports stake_change as the primary driver.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage
Sector / macro signals